Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent hispanic female

CNS Spectrums

Volumn 12, Issue 11, 2007, Pages 818-820

  Afzal, Khalid I ^a   Briones, David F ^a   DeVargas, Cecilia ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE; TRAZODONE;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; BREAST DISCHARGE; BULIMIA; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; GALACTORRHEA; HUMAN; INSOMNIA; LABORATORY TEST; POLYDIPSIA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 37049004510     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900015558     Document Type: Article

References (16)

1. Vieweg WV, Sood AB, Pandurangi A, Silverman JJ. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain? Acta Psychiatr Scand. 2005;111:177-184.
2. Physicians' Desk Reference. 60th ed. Montvale, NJ: Medical Economics; 2006.
3. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004;24:429-436.
4. Bersani G, Pesaresi L, Orlandi V, Gherardelli S, Pancheri P. Atypical antipsychotics and polydipsia: a cause or a treatment? Hum Psychopharmacol. 2007;22:103-107.
5. Martin A, L'Ecuyer S. Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry. 2002;11:129-133.
6. Findling RL, McNamara NK, Gracious BL. Antipsychotic agents: traditional and atypical. In: Martin A, Scahill L, Charney DS, Leckman JF, eds. Pediatric Psychopharmacology: Principles and Practice. New York, NY: Oxford University Press; 2003:328-337.
7. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry. 2005;162:1010-1012.
8. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry. 2003;64:1362-1369.
9. Oades RD, Daniels R. Subclinical polydipsia and polyuria in young patients with schizophrenia or obsessive-compulsive disorder vs normal controls. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:1329-1344.
10. Popovic V, Doknic M, Marie N, et al. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology. 2007;85:249-256.
11. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 2007;104:3456-3459.
12. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41:337-343.
13. Mahendran R, Liew E, Subramaniam M. De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in Asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study. J Clin Psychiatry. 2007;68:542-545.
14. Faucher S, Dardennes R, Ghaëm O, Guelfi JD. Obsessive-compulsive symptoms treatment in: schizophrenia [French]. Can J Psychiatry. 2005;50:423-428.
15. Khalili H, Dashti-Khavidaki S, Okhovatpour H, Ghaeli P. Effects of risperidone on lipid profile. Ann Pharmacother. 2007;41:899-900.
16. Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, Herbison P. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Sat 2007;30:569-579.